title: Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.
abstract: OBJECTIVE
  To determine in vivo cortical acetylcholinesterase (AChE) activity and cognitive effects in subjects with mild Alzheimer's disease (AD, n = 14) prior to and after 12 weeks of donepezil therapy.
  
  
  METHODS
  Cognitive and N-[(11)C]methyl-piperidin-4-yl propionate ([(11)C]PMP) AChE positron emission tomography (PET) assessments before and after donepezil therapy.
  
  
  RESULTS
  Analysis of the PET data revealed mean (temporal, parietal, and frontal) cortical donepezil induced AChE inhibition of 19.1% (SD 9.4%) (t = -7.9; p<0.0001). Enzyme inhibition was most robust in the anterior cingulate cortex (24.2% (6.9%), t = -14.1; p<0.0001). Donepezil induced cortical inhibition of AChE activity correlated with changes in the Stroop Color Word interference scores (R(2) = 0.59, p<0.01), but not with primary memory test scores. Analysis of the Stroop test data indicated that subjects with AChE inhibition greater than the median value (>22.2%) had improved scores on the Stroop Color Word Test compared with subjects with less inhibition who had stable to worsening scores (t = -2.7; p<0.05).
  
  
  CONCLUSIONS
  Donepezil induced inhibition of cortical AChE enzyme activity is modest in patients with mild AD. The degree of cortical enzyme inhibition correlates with changes in executive and attentional functions.
authors.affiliation: University of Pittsburgh, Liliane S Kaufmann Building, Suite 811, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA. nbohnen@pitt.edu
authors.forename: N I
authors.initials: NI
authors.lastname: Bohnen
authors.forename: D I
authors.initials: DI
authors.lastname: Kaufer
authors.forename: R
authors.initials: R
authors.lastname: Hendrickson
authors.forename: L S
authors.initials: LS
authors.lastname: Ivanco
authors.forename: B J
authors.initials: BJ
authors.lastname: Lopresti
authors.forename: R A
authors.initials: RA
authors.lastname: Koeppe
authors.forename: C C
authors.initials: CC
authors.lastname: Meltzer
authors.forename: G
authors.initials: G
authors.lastname: Constantine
authors.forename: J G
authors.initials: JG
authors.lastname: Davis
authors.forename: C A
authors.initials: CA
authors.lastname: Mathis
authors.forename: S T
authors.initials: ST
authors.lastname: Dekosky
authors.forename: R Y
authors.initials: RY
authors.lastname: Moore
mesh_terms: D000110:Acetylcholinesterase / Q000187:drug effects* / Q000494:pharmacology*; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy*; D001288:Attention / Q000187:drug effects; D002540:Cerebral Cortex / Q000201:enzymology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D000077265:Donepezil; D005260:Female; D006801:Humans; D007189:Indans / Q000494:pharmacology*; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D049268:Positron-Emission Tomography
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil; D000110:Acetylcholinesterase
references.citation: J Cereb Blood Flow Metab. 1999 Oct;19(10):1150-63
references.pmid: 10532640
references.citation: Neurology. 1999 Mar 10;52(4):691-9
references.pmid: 10078712
references.citation: Am J Psychiatry. 2000 Jan;157(1):4-15
references.pmid: 10618007
references.citation: Nucl Med Commun. 2000 Jan;21(1):37-41
references.pmid: 10717900
references.citation: J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):209-18
references.pmid: 11001599
references.citation: Ann Neurol. 2000 Sep;48(3):391-5
references.pmid: 10976649
references.citation: Neurology. 2001 Feb 13;56(3):408-10
references.pmid: 11171913
references.citation: J Cereb Blood Flow Metab. 2001 Mar;21(3):295-306
references.pmid: 11295884
references.citation: Neurobiol Dis. 2002 Feb;9(1):88-93
references.pmid: 11848688
references.citation: Synapse. 2002 Jul;45(1):1-9
references.pmid: 12112408
references.citation: Clin Pharmacokinet. 2002;41(10):719-39
references.pmid: 12162759
references.citation: J Clin Psychopharmacol. 2002 Dec;22(6):615-20
references.pmid: 12454562
references.citation: Z Zellforsch Mikrosk Anat. 1966;69:334-43
references.pmid: 5973099
references.citation: Percept Mot Skills. 1971 Oct;33(2):575-81
references.pmid: 5124116
references.citation: Arch Neurol. 1974 Feb;30(2):113-21
references.pmid: 4359364
references.citation: Neurology. 1984 Jul;34(7):939-44
references.pmid: 6610841
references.citation: Pharmacol Biochem Behav. 1985 Jul;23(1):125-35
references.pmid: 4041042
references.citation: Ann Neurol. 1987 Jul;22(1):26-30
references.pmid: 3631918
references.citation: Ann Neurol. 1990 Aug;28(2):117-21
references.pmid: 2221841
references.citation: Brain. 1992 Dec;115 ( Pt 6):1701-25
references.pmid: 1486457
references.citation: J Comput Assist Tomogr. 1993 Jul-Aug;17(4):536-46
references.pmid: 8331222
references.citation: Dementia. 1993 Jan-Feb;4(1):54-8
references.pmid: 8358507
references.citation: J Nucl Med. 1995 Jan;36(1):93-6
references.pmid: 7799090
references.citation: Psychopharmacology (Berl). 1993;110(4):395-401
references.pmid: 7870908
references.citation: Alzheimer Dis Assoc Disord. 1995;9 Suppl 2:43-9
references.pmid: 8534423
references.citation: Cereb Cortex. 1996 Mar-Apr;6(2):165-77
references.pmid: 8670647
references.citation: Nucl Med Biol. 1994 Aug;21(6):801-8
references.pmid: 9234329
references.citation: Lancet. 1997 Jun 21;349(9068):1805-9
references.pmid: 9269216
references.citation: Neurology. 1998 Jan;50(1):136-45
references.pmid: 9443470
references.citation: Nucl Med Biol. 1998 Nov;25(8):751-4
references.pmid: 9863562
references.citation: Brain. 1998 Dec;121 ( Pt 12):2249-57
references.pmid: 9874478